Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia

Abstract Background Preliminary data from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia patients indicate that a cytokine storm may increase morbidity and mortality. Tocilizumab (anti-IL-6R) is approved by the Food and Drug Administration for treatment of cytokine storm asso...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2020-12, Vol.71 (12), p.3168-3173
Main Authors: Jordan, Stanley C, Zakowski, Phillip, Tran, Hai P, Smith, Ethan A, Gaultier, Cyril, Marks, Gregory, Zabner, Rachel, Lowenstein, Hayden, Oft, Jillian, Bluen, Benjamin, Le, Catherine, Shane, Rita, Ammerman, Noriko, Vo, Ashley, Chen, Peter, Kumar, Sanjeev, Toyoda, Mieko, Ge, Shili, Huang, Edmund
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Compassionate Use Trials
COVID-19
Humans
Major
Male
Middle Aged
SARS-CoV-2
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Preliminary data from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia patients indicate that a cytokine storm may increase morbidity and mortality. Tocilizumab (anti-IL-6R) is approved by the Food and Drug Administration for treatment of cytokine storm associated with chimeric antigen receptor T-cell therapy. Here we examined compassionate use of tocilizumab in patients with SARS-CoV-2 pneumonia. Methods We report on a single-center study of tocilizumab in hospitalized patients with SARS-CoV-2 pneumonia. All patients had confirmed SARS-CoV-2 pneumonia and oxygen saturations
ISSN:1058-4838
1537-6591
1537-6591
DOI:10.1093/cid/ciaa812